| Variables | Dead | Survivors | p-value |
| Subjects n | 79 | 318 | |
| Age years | 71.6±11.1 | 56.16±17.3 | 0.0001 |
| Male | 49 (62) | 127 (39.9) | 0.0001 |
| Body mass index kg·m−2 | 26.5±4.3 | 25.9±4.3 | 0.32 |
| Dyspnoea mMRC score | 2.71±0.97 | 1.25±1 | 0.0001 |
| Smoking pack-years | 9.6±27.7 | 4.9±15.9 | 0.13 |
| Appearance of sputum | 0.028 | ||
| Mucous | 13 (16.5) | 88 (27.7) | |
| Mucopurulent | 20 (25.3) | 86 (27) | |
| Purulent | 14 (17.7) | 26 (8.2) | |
| Respiratory insufficiency | 21 (27) | 18 (5.7) | 0.0001 |
| Number of lobes affected | 2.82±1.2 | 2.35±1.19 | 0.001 |
| Idiopathic bronchiectasis | 29 (36.7) | 125 (39.3) | 0.38 |
| FEV1 % predicted | 46.6±20.3 | 73.9±23.7 | 0.0001 |
| FVC % predicted | 64.1±19.3 | 78.9±19.2 | 0.0001 |
| Chronic colonisation | |||
| Pseudomonas aeruginosa | 38 (48.1) | 88 (27.7) | 0.0001 |
| Haemophilus influenzae | 16 (20.3) | 46 (14.5) | 0.11 |
| Multiresistant Gram-negative bacteria | 6 (7.6) | 12 (3.8) | 0.13 |
| Isolation of Staphylococcus aureus | 5 (6.3) | 14 (4.4) | 0.32 |
| Isolation of fungi | 22 (27.8) | 65 (20.4) | 0.10 |
| Isolation of atypical mycobacteria | 6 (7.6) | 8 (2.5) | 0.04 |
| Exacerbations in previous year | 3±2.7 | 2.32±1.86 | 0.07 |
| Hospitalisations in previous year | 1.39±1.85 | 0.57±1.1 | 0.013 |
| Chronic treatment | |||
| Systemic antibiotics | 10 (12.7) | 18 (5.7) | 0.01 |
| Inhaled antibiotics | 27 (34.1) | 48 (15.1) | 0.0001 |
| Macrolides | 18 (22.8) | 37 (11.6) | 0.011 |
| Oral corticosteroids | 6 (7.6) | 12 (3.8) | 0.12 |
Data are presented as mean±sd or n (%), unless otherwise stated. mMRC: modified Medical Research Council; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.